Herniectomy Versus Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Medtronic Spinal & Biologics ECA
ClinicalTrials.gov Identifier:
NCT00749996
First received: September 9, 2008
Last updated: February 25, 2013
Last verified: December 2012

September 9, 2008
February 25, 2013
November 2006
August 2013   (final data collection date for primary outcome measure)
To demonstrate a statistically significant difference in the relief of back pain between both treatment groups. The endpoint will be the difference between baseline and 6-month of the patient's back-pain score on a Visual Analogue Scale (VAS). [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00749996 on ClinicalTrials.gov Archive Site
To demonstrate a statistically significant difference in the reduction of disability between both treatment groups. The endpoint will be the difference between baseline and 12 months of the patient's score on the Oswestry Disability Index (ODI). [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Herniectomy Versus Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease
Herniectomy vs. Herniectomy With a Spinal Stabilization System for the Treatment of Complex Disc Disease

The study aims at assessing the short and long-term effectiveness and patient perception of benefit with the use of a DIAM™ Spinal Stabilization System in the treatment of complex disc disease at a single level from L2 to L5.

This study is a multi-center, prospective, randomized, controlled trial. Patients will be randomized in 2 groups:

Investigational group: a single level herniectomy procedure, followed by placement of the DIAMTM Spinal Stabilization System; Control group: a single level herniectomy procedure; After surgery, patients will be followed for a 2 years period with required follow up visits at 6 weeks, 3 months, 6 months, 1 year, 2 years and 4 years (optional visit).

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Sciatica
  • Lumbar Degenerative Disc Disease
  • Device: DIAM™ Spinal Stabilization System
    The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.
  • Procedure: Herniectomy
    Herniectomy is defined as the "removal of the extruded/protruded/sequestrated disc material". This is done by probing the annulus and disc space and removing all mobile disc fragments.
  • Experimental: Investigational group
    Single level herniectomy followed by placement of the DIAM™ Spinal Stabilization System
    Intervention: Device: DIAM™ Spinal Stabilization System
  • Active Comparator: Control group
    Single level herniectomy
    Intervention: Procedure: Herniectomy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
165
August 2013
August 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Has a history of sciatica (radicular pain) for at least 6 weeks, but not more than 1 year secondary to one symptomatic lumbar disc herniation at the levels L2-L5 as confirmed by patient history and clinical evaluation, and without major neurological impairment (i.e. not less than M 3/5; Medical Research Council Classification);
  • Has a history of continuous low back pain for no more than 1 year secondary to lumbar degenerative disc disease (intermittent back pain may occur for more than a year);
  • Has pre-treatment back pain score greater than or equal to 3, concomitant with leg pain score greater than or equal to 6. Leg pain score must be greater than back pain score (pain intensity score measured on a 10 cm VAS scale);
  • Has one symptomatic disc herniation: protrusion, extrusion or sequestration (Milette & Fardon, 2001) as confirmed by MRI at the target level;
  • Evidence of disc degeneration ≤ Grade IV at the target and adjacent levels as confirmed by MRI (Pfirrmann, 2001);
  • Has an Oswestry Disability Index (ODI) score ≥ 34%;
  • Has been treated non-operatively (e.g. bed rest, physical therapy, medications, TENS, manipulation, hydrotherapy, acupressure/acupuncture, massage, bracing and/or spinal injections) for at least 6 continuous weeks unless strong clinical grounds for expediting surgery;
  • Patient male or female, age 20-60 years inclusive and is skeletally mature;
  • Is willing and able to comply with the study plan and able to provide an informed consent;

Exclusion Criteria:

  • Has a primary diagnosis of spinal disorder other than degenerative disc at the involved level;
  • Has a symptomatic disc herniation at more than one lumbar level;
  • Requires a herniectomy at more than one lumbar level;
  • Has a disc degeneration at the treated and adjacent levels > Grade IV (Pfirrmann, 2001);
  • Has a decrease of disc height ≥ 30% as measured by the center of the disc space, and compared to the disc space at the next superior spinal level;
  • Has Modic changes on MRI greater than Grade I at the target level;
  • Has Modic changes on MRI at the adjacent levels;
  • Has an advanced degree of retrolisthesis as shown by lateral X-rays (> 25%, i.e. grade I as per Meyerding);
  • Has a clinical evidence of lysis, antero listhesis or scoliosis (Cobb angle more than 10°);
  • Has signs of segmental instability: more than 4 mm of translation or more than 10° angular motion between adjacent end plates (comparing flexion and extension views);
  • Has congenital or iatrogenic posterior element insufficiency (e.g. facet resection, spondylolysis, pars fracture, or Spinal Bifida Occulta);
  • Has had any previous lumbar spine surgery;
  • Has a Waddell signs of inorganic behaviour score greater than or equal to 3;
  • Has evidence of an active disruptive psychiatric disorder, cognitive impairment or other known condition, significant enough to impact the perception of pain, precludes surgical procedure, clinical evaluation and/or ability to evaluate treatment outcome as determined by investigator;
  • Has a known allergy to silicone, polyethylene, or titanium;
  • Is an alcohol and /or drug abuser, as defined by currently undergoing treatment for alcohol and/or drug abuse;
  • Has obesity defined by BMI greater than or equal to 35;
  • Inability to complete the questionnaires;
  • Planned pregnancy during the course of the study;
  • Previous enrollment into a spine study;
  • Vulnerable patients or unable to exercise free informed consent;
Both
20 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Czech Republic,   Germany,   Italy,   Poland,   Spain,   Switzerland,   United Kingdom
 
NCT00749996
DIAM™ Study
No
Medtronic Spinal & Biologics ECA
Medtronic Spinal & Biologics ECA
Not Provided
Principal Investigator: Ferdiand Krappel, Dr. Spitalzentrum Oberwallis, Brig
Medtronic Spinal & Biologics ECA
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP